Retroperitoneal sarcoma
Prepared with OnCo (onco.cc/prep/retroperitoneal-sarcoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
16 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Histological subtype and grade on preoperative core biopsy, MDM2 amplification, Multifocality and growth rate at recurrence, Sarculator nomogram risk), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (primary, resectable), which of the standard options do you recommend and why?
- 6.How do the results of STRASS (EORTC 62092) apply to someone like me?
- 7.For my situation (high-risk dedifferentiated liposarcoma or leiomyosarcoma), which of the standard options do you recommend and why?
- 8.Am I a candidate for Doxorubicin, Ifosfamide, Dacarbazine, and what side effects should I expect?
- 9.For my situation (recurrent or metastatic), which of the standard options do you recommend and why?
- 10.Am I a candidate for Trabectedin, Eribulin, Pazopanib, and what side effects should I expect?
- 11.How do the results of LMS-04 apply to someone like me?
- 12.Are there clinical trials I could join, for example of MDM2 inhibitors, Eribulin, Trabectedin?
- 13.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 14.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 15.I read that “Liposarcoma recurs in the abdomen in most patients even after complete surgery”. How does that affect my plan?
- 16.I read that “Neither radiotherapy nor chemotherapy has a proven adjuvant benefit”. How does that affect my plan?
The words I may hear
- FNCLCC grade (soft-tissue sarcoma): The FNCLCC grade is a 1-to-3 score for soft-tissue sarcomas based on how abnormal, how fast-dividing, and how much dead tissue the tumour shows; grade drives whether chemotherapy is considered.
Tests and results to bring
Biomarker results to ask for: Histological subtype and grade on preoperative core biopsy, MDM2 amplification (liposarcoma), Multifocality and growth rate at recurrence, Sarculator nomogram risk.
Scans and tests linked to this cancer: CT (computed tomography).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Primary, resectable: Single-stage complete en bloc resection with adjacent organs in a sarcoma reference centre, after core biopsy and multidisciplinary planning; preoperative radiotherapy not routine after STRASS, considered in well-differentiated and low-grade dedifferentiated liposarcoma. (STRASS (EORTC 62092), IMRT / IGRT (modern external beam), CT (computed tomography), FNCLCC grade (soft-tissue sarcoma))
- High-risk dedifferentiated liposarcoma or leiomyosarcoma: Neoadjuvant chemotherapy within STRASS2 (doxorubicin-ifosfamide or doxorubicin-dacarbazine) or up-front surgery; no proven adjuvant therapy. (Doxorubicin, Ifosfamide, Dacarbazine)
- Recurrent or metastatic: Repeat resection for slowly growing, unifocal recurrence; histology-driven chemotherapy (doxorubicin plus trabectedin for leiomyosarcoma, LMS-04; eribulin or trabectedin for liposarcoma); MDM2 inhibitor trials. (Trabectedin, LMS-04, Eribulin, MDM2 inhibitors, Pazopanib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.